Tigecycline
Loading drug information...
Failed to Load Drug Information
Please check your internet connection and try again.
Last updated: June 2025
For educational purposes only
Clinical Reference
# Tigecycline
## Overview
- **Classification**: Glycylcycline antibiotic, a tetracycline derivative.
- **Mechanism**: Binds to the 30S ribosomal subunit, blocking tRNA binding and inhibiting bacterial protein synthesis.
## Primary Indications
1. **Complicated Skin and Skin Structure Infections (cSSSI)** - caused by susceptible Gram-positive, Gram-negative, and anaerobic bacteria.
2. **Complicated Intra-abdominal Infections (cIAI)** - caused by susceptible Gram-positive, Gram-negative, and anaerobic bacteria.
3. **Community-Acquired Bacterial Pneumonia (CABP)** - caused by susceptible Gram-positive and Gram-negative bacteria.
## Adult Dosing
### Standard Dosing
**Complicated Skin and Skin Structure Infections (cSSSI), Complicated Intra-abdominal Infections (cIAI), Community-Acquired Bacterial Pneumonia (CABP)**
- **Loading Dose**: **100 mg**
- **Maintenance Dose**: **50 mg**
- **Frequency**: Every **12 hours** (after loading dose)
- **Route**: Intravenous (IV) infusion over **30-60 minutes**
- **Duration**: **5 to 14 days** (or as clinically indicated)
- **Maximum Dose**: **50 mg** per dose (after loading dose)
### Dose Adjustments
- **Renal Impairment**: No dose adjustment required for any degree of renal impairment, including hemodialysis.
- **Hepatic Impairment**:
- **Mild to Moderate (Child-Pugh A or B)**: No dose adjustment needed.
- **Severe (Child-Pugh C)**:
- Loading dose remains **100 mg**.
- Maintenance dose should be reduced to **25 mg** every **12 hours**.
- Closely monitor response and adverse effects.
- **Elderly Patients**: No specific dose adjustment solely based on age. Monitor renal and hepatic function as appropriate.
## Pediatric Dosing
**⚠️ IMPORTANT SAFETY WARNING**: Tigecycline is **NOT RECOMMENDED** for use in pediatric patients younger than 18 years. Increased mortality has been observed in pediatric patients treated with tigecycline compared to other antibiotics in clinical trials. Tigecycline may also cause permanent tooth discoloration and inhibition of bone growth in pediatric patients. Safety and effectiveness are not established. Use only when other antibiotics are not suitable for severe, life-threatening infections, and potential benefits outweigh significant risks.
### Neonates (0-28 days)
- Tigecycline is **not recommended** and generally **contraindicated** in this age group due to safety concerns.
- **Special Notes**: No established dose. Risk of permanent tooth discoloration, bone growth inhibition, and increased mortality.
### Infants (1-12 months)
- Tigecycline is **not recommended** in this age group.
- **Special Notes**: No established dose. Risk of permanent tooth discoloration, bone growth inhibition, and increased mortality.
### Children (1-12 years)
- Tigecycline is **not recommended** in this age group.
- **Limited data (off-label use only for life-threatening infections when alternatives are not available):**
- **Age 8 to <12 years**:
- **Loading Dose**: **1.2 mg/kg** IV (not to exceed **50 mg**).
- **Maintenance Dose**: **0.75 mg/kg** IV every **12 hours** (not to exceed **25 mg** per dose).
- **Route**: IV infusion over **30-60 minutes**.
- **Maximum**: **25 mg** per maintenance dose.
- **Age <8 years**: No data available.
- **Special Notes**: Emphasize risks of increased mortality, tooth discoloration, and bone growth inhibition.
### Adolescents (13-18 years)
- Tigecycline is **not recommended** in this age group.
- **Limited data (off-label use only for life-threatening infections when alternatives are not available):**
- **Age 12 to <18 years**:
- **Loading Dose**: **1.2 mg/kg** IV (not to exceed **100 mg**).
- **Maintenance Dose**: **0.75 mg/kg** IV every **12 hours** (not to exceed **50 mg** per dose).
- **Route**: IV infusion over **30-60 minutes**.
- **Maximum**: **50 mg** per maintenance dose.
- **Special Notes**: Emphasize risks of increased mortality, tooth discoloration, and bone growth inhibition. Use adult dosing if adult weight/size is reached and risks are carefully weighed.
## Safety Information
### Contraindications
- **Absolute**: Known hypersensitivity to tigecycline or any tetracycline antibiotic.
- **Absolute**: Pediatric patients younger than **8 years** (due to permanent tooth discoloration and bone growth inhibition, plus increased mortality). Generally **not recommended for <18 years**.
- **Relative**: Pregnancy (Category D) and breastfeeding.
### Common Adverse Effects
- **Very Common (>10%)**: Nausea, vomiting, diarrhea, abdominal pain, headache.
- **Common (1-10%)**: Dyspepsia, elevated LFTs (AST/ALT), injection site reactions, increased amylase/lipase, dizziness.
- **Serious but Rare**:
- Increased all-cause mortality (Black Box Warning).
- Anaphylaxis/severe hypersensitivity reactions.
- Pancreatitis (acute).
- Clostridioides difficile-associated diarrhea (CDAD).
- Photosensitivity reactions.
- Permanent tooth discoloration and bone growth inhibition in children.
### Key Drug Interactions
- **Warfarin**: May prolong prothrombin time (INR) due to potential inhibition of gut flora vitamin K synthesis.
- **Clinical Significance**: Increased risk of bleeding.
- **Monitoring Requirement**: Monitor INR closely; adjust warfarin dose as needed.
- **Oral Contraceptives**: May decrease efficacy of oral contraceptives.
- **Clinical Significance**: Risk of unintended pregnancy.
- **Monitoring Requirement**: Advise patients to use alternative or additional birth control methods.
- **Cyclosporine**: No significant pharmacokinetic interaction; however, theoretical concern for additive hepatotoxicity.
- **Clinical Significance**: Monitor LFTs.
## Monitoring & Follow-up
- **Before Treatment**:
- Obtain baseline liver function tests (LFTs), bilirubin, and pancreatic enzymes (amylase/lipase).
- Review patient allergies and medication history.
- **During Treatment**:
- Monitor LFTs and bilirubin (especially in severe hepatic impairment).
- Monitor pancreatic enzymes (amylase/lipase) if pancreatitis is suspected.
- Monitor for signs of superinfection (e.g., C. difficile).
- Assess clinical response and adverse effects (nausea, vomiting, injection site reactions).
- **Clinical Signs**:
- Look for improvement in infection signs (fever, WBC count, localized symptoms).
- Watch for signs of pancreatitis (severe abdominal pain, nausea, vomiting).
- Monitor for allergic reactions (rash, itching, dyspnea).
## Clinical Pearls
- 💡 **Boxed Warning**: Tigecycline carries a Black Box Warning for increased all-cause mortality compared to other antibiotics. Consider alternatives if available.
- 💡 **GI Effects**: Nausea and vomiting are common, often dose-related. Administering over **60 minutes** instead of 30 minutes may improve tolerability.
- 💡 **Spectrum**: Has broad spectrum activity including MRSA, VRE, ESBL-producing bacteria, and anaerobes, but *not* Pseudomonas or Proteus.
- 💡 **Distribution**: Achieves high concentrations in tissues (e.g., skin, soft tissue, lung) but low concentrations in blood. Not ideal for bloodstream infections unless absolutely necessary.
- 💡 **Discoloration**: Advise patients about potential permanent tooth discoloration if used in pediatric patients.
> **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.